# Phase 1 Trial of Ebola Vaccine in Mali

> **NCT02267109** · PHASE1 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 91 (actual)

## Conditions studied

- Ebola Virus Disease
- Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
- **BIOLOGICAL:** Booster-MVA-BN® Filo or saline placebo

## Key facts

- **NCT ID:** NCT02267109
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-04-20
- **Final completion:** 2016-04-20
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2019-09-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267109, "Phase 1 Trial of Ebola Vaccine in Mali". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02267109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*